Abstract 19918: Spatial Thermodynamics and Characteristics of Lesions Created by a Novel Irrigated Radiofrequency Balloon Ablation Catheter in the Canine Heart
Introduction: Balloon catheters have been developed to treat atrial fibrillation by isolating pulmonary veins (PVI) using a single energy shot. This study was conducted to investigate the biophysics and lesion characteristics of a newly developed 28mm multi-electrode radiofrequency open irrigated balloon (RFIB) ablation catheter with 10 electrode bands.
Methods: Three normal dogs underwent catheter ablation using this novel RFIB catheter. PVI was performed using settings of 15W, irrigation flow of 50 ml/min, and RF application time of 60sec. Balloon position and occlusion for each vein were assessed by intracardiac echocardiography (ICE) and fluoroscopy. The tissue temperature was monitored during ablation using thermocouples implanted to the LA-PV junction (left superior PV [LSPV], left inferior PV [LIPV] and right inferior PV [RIPV]), phrenic nerve, and luminal esophagus. These data were compared to conventional PVI using a standard irrigated-tip catheter with settings of 30-35W, irrigation flow 30 ml/min and 30 sec. Gross pathologic and histologic characteristics of the lesions were examined.
Results: A total of 11 PVs (3 LSPVs, 3 right superior PVs [RSPV], 3 LIPVs and 2 RIPVs) were ablated using RFIB catheter. PV isolation was achieved in 9/11 (81.8%) PVs and transmural PV lesion circumferentiality was 98.4 ± 3.2% with 1 or 2 RF applications (1.3 ± 0.5/PV). Figure shows the relationship between maximum tissue temperature and distance. Maximum tissue temperature at the distance of <10mm from catheter was not different between RFIB and standard catheter (46.8 ±8.6 vs. 45.3 ± 8.0 °C at LSPV, p=0.604, 45.2 ± 6.5 vs. 44.9 ± 7.5 °C at LI/RIPV, p=0.831, 38.7 ± 5.7 vs. 40.9 ± 5.8 °C at esophagus, p=0.078, respectively).
Conclusions: This novel RF irrigated balloon catheter showed the potential for creating circumferential, transmural lesions with a “single shot” with overall effects equivalent to point-by-point ablation.
Author Disclosures: A. Suzuki: None. H. Lehmann: None. S. Wang: None. K.D. Parker: None. M. Rettmann: None. K.B. Viker: None. S.B. Johnson: None. D.L. Packer: Research Grant; Significant; American Heart Association Foundation Award, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic CryoCath LP, NIH, St. Jude Medical, Siemens, Thermedical. Honoraria; Significant; Abbott Laboratories/Topera, Aperture Diagnostics $0, Biosense Webster $0, Boston Scientific $0, CardioFocus $0, CardioInsight $0, Johnson & Johnson Healthcare Systems $0, Johnson & Johnson $0, MediaSphere Medical, , Medtronic CryoCath $0, Siemens $0, St. Jude Medical $0, Topera. Other; Significant; Royalties: St. Jude Medical, Royalties: Analyze-AVW technology, Royalties: Wiley and Sons.
- © 2016 by American Heart Association, Inc.